Of Price And Premiums: Medicare Has Put Alzheimer’s Drug Sponsors On Notice
Medicare will be closely watching for pricing decisions by Eli Lilly, Eisai and Roche once the companies gain US marketing approval for their amyloid-directed monoclonal antibody drugs for Alzheimer’s disease.
You may also be interested in...
Eisai Pricing For Lecanemab Reflects Concern With Medicare ‘Sustainability,’ ‘Giving Back,’ Firm Says
Despite internal modeling indicating lecanemab offers a ‘societal value’ of around $37,600 per year, the company has decided on a list price of around $26,500 annually to moderate the impact on Medicare and patients.
Eisai/Biogen’s Lecanemab: Pricing Pressure Builds Ahead Of Likely US Approval Of Alzheimer’s Drug
After the commercial and public relations debacle driven by Biogen’s original pricing for the companies’ predecessor drug for Alzheimer’s, Aduhelm, Eisai is feeling the heat to ensure the US price for lecanemab is in line with stakeholder expectations.
Medicaid Adoption Of Medicare CED Restrictions For Alzheimer’s Drugs Weighed By MACPAC
Medicaid advisory panel members suggest states should have the same flexibility as Medicare to adopt coverage with evidence development requirements for drugs with limited supporting evidence.